Combined serotonin-5-HT2 and dopamine-D2
โ
G. Bersani; G. M. Bressa; G. Meco; S. Marini; F. Pozzi
๐
Article
๐
1990
๐
John Wiley and Sons
๐
English
โ 580 KB
Previous studies suggested a therapeutic action of the selective serotonin 5-HT2-antagonist ritanserin on negative symptoms of schizophrenia and on neuroleptic-induced parkinsonism. In this open trial the effect of risperidone, a combined serotonin-5-HT2-and dopamine-D,-antagonist, was studied on a